Tenofovir-Based Highly Active Antiretroviral Therapy Is Associated with Superior CD4 T Cells Repopulation Compared to Zidovudine-Based HAART in HIV 1 Infected Adults
Table 1
Demographic and baseline characteristics of the study participants at diagnosis.
Variable
Observations
Mean age
Std. Dev.
Min
Max
Females
69 (65.1%)
39.09
11.8
20
78
Males
37 (34.9%)
42.30
11.0
22
72
Total
106
42.63
11.4
20
78
Distribution of participants across treatment groups before and during follow-up
Treatment group
Initial distribution
Follow-up distribution
TLE (tenofovir cohort)
80 (75.5%)
68 (76.4%)
ZLE (zidovudine cohort)
26 (24.5%)
21 (23.6%)
Total
106 (100%)
89 (100%)
Comorbidities
Number of participants
Tuberculosis
21
Hepatitis B
7
Hepatitis C
1
Kaposi sarcoma
4
Cerebral toxoplasmosis
1
Total comorbidities
34
Stage of HIV (CD4 count/cells/µL)
Number of participants
Percentage Freq. (%)
Stage I (≥500)
11
10.4
Stage II (200–499)
35
33.0
Stage III (0–199)
60
56.6
Total number
106
100
The table shows the baseline characteristics of study participants before and during the initiation of therapy. It shows their age distribution across gender at diagnosis and the comorbidity profile of participants determined before and during treatment with HAART. The stage of HIV was determined at baseline depicting the degree of progression to AIDS using the CD4 T cells count.
